Need help?
news

Launch of RGCC CAMBISeq and RGCC CeFSeq

In as little as two weeks, patients and clinicians can gain access to a next-generation genetic test provided by RGCC that can analyse the sequence of both DNA and RNA. The RGCC CAMBISeq (Cancer Analysis, Mutational Burden and Instability Sequencing) test sequences DNA and RNA – the nucleic acids that carry genomic sequence information and […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more